Trial Profile
Phase IB/II Study of Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 May 2022
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Mocetinostat (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions
- 10 May 2022 Status changed from active, no longer recruiting to completed.
- 18 Feb 2021 Planned End Date changed from 1 Apr 2021 to 1 Apr 2022.
- 18 Feb 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Apr 2022.